A Study to Compare the Cognitive Effect of Solifenacin 5mg Once-daily and Oxybutynin 5mg Twice-daily After Chronic Dosing Versus Placebo in Subjects 75 Years and Over With Mild Cognitive Impairment - A Double-blind, Randomized, Multi-center Study

Trial Profile

A Study to Compare the Cognitive Effect of Solifenacin 5mg Once-daily and Oxybutynin 5mg Twice-daily After Chronic Dosing Versus Placebo in Subjects 75 Years and Over With Mild Cognitive Impairment - A Double-blind, Randomized, Multi-center Study

Completed
Phase of Trial: Phase IV

Latest Information Update: 01 Jul 2013

At a glance

  • Drugs Oxybutynin; Solifenacin
  • Indications Overactive bladder
  • Focus Adverse reactions
  • Acronyms SENIOR
  • Sponsors Astellas Pharma
  • Most Recent Events

    • 28 Feb 2012 Results presented at the 27th Congress of the European Association of Urology.
    • 10 Feb 2011 Actual end date (Dec 2010) added as reported by ClinicalTrials.gov.
    • 10 Feb 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top